Francisco Badar, MD
Family Medicine · Cerritos, CANPI 1760667729
Payments from drug & device makers
Across 651 payments — averaging $3265.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$501K
- GRT US Holding, Inc.$416K
- Taro Pharmaceuticals USA, Inc.$232K
- Amgen$184K
- Regeneron$171K
- Bausch Health US, LLC$154K
- plus $468K from 28 others
Across 12 payments — averaging $35,760 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Overseas Pharmaceuticals LLC$368K
- Eli Lilly$54K
- Sanofi-aventis U.S. LLC$6K
- HRA Pharma$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 38 | $500,971 |
| GRT US Holding, Inc. | 57 | $415,957 |
| Taro Pharmaceuticals USA, Inc. | 19 | $232,110 |
| Amgen(2 entities) | 22 | $184,167 |
| Regeneron | 13 | $170,582 |
| Bausch Health US, LLC | 9 | $154,258 |
| Journey Medical Corporation | 6 | $130,628 |
| Eli Lilly | 7 | $85,722 |
| Pfizer | 13 | $67,907 |
| AstraZeneca | 48 | $41,807 |
| Dermavant Sciences, Inc. | 189 | $41,671 |
| Sanofi Pasteur Inc. | 2 | $20,316 |
| Dexcom, Inc. | 16 | $19,328 |
| AbbVie(2 entities) | 9 | $15,389 |
| Sanofi-aventis U.S. LLC | 6 | $15,245 |
| Sanofi US Services Inc. | 1 | $12,335 |
| Janssen Research & Development, LLC | 2 | $3,700 |
| Bayer | 14 | $3,576 |
| HRA Pharma | 1 | $3,500 |
| Galderma Laboratories, L.p. | 3 | $1,975 |
| Endo USA, Inc. | 10 | $1,142 |
| Johnson & Johnson | 34 | $1,002 |
| Novo Nordisk | 45 | $719 |
| Boehringer Ingelheim | 34 | $710 |
| Lilly USA, LLC | 27 | $528 |
| Myovant Sciences Inc. | 1 | $250 |
| Amarin Pharma, Inc. | 16 | $238 |
| Gilead | 2 | $39 |
| Abbott | 2 | $32 |
| Novartis | 1 | $23 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $12 |
How this compares
$2,125,880 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family medicine in Cerritos
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.